ClinicalTrials.gg
Not yet recruitingNCT07801976Updated Nov 16, 2026

Positron Emission Tomography (PET) Imaging of Reactive Oxygen and Nitrogen Species: Human Observation of Retention and Safety of [18F]-Fluoroedaravone

An Early Phase 1 interventional study of [18F]Fluoroedaravone ([18F]FEDV) and PET/CT Imaging in Healthy Volunteer, sponsored by St. Jude Children's Research Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by St. Jude Children's Research Hospital · Early Phase 1, Interventional, and Basic science

Updated Nov 16, 2026Eligibility revisedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This first-in-human research study will test the safety of a new PET imaging tracer called[18F]fluoroedaravone ([18F]FEDV) in healthy adults. Participants will receive one injection of the tracer and undergo several PET/CT scans over about 3 hours. Researchers will collect blood and urine samples, check vital signs and heart activity (ECGs), and ask participants about any symptoms to learn how the tracer moves through and leaves the body and to monitor for side effects. Information from this study will help researchers develop this imaging tracer for future studies of oxidative stress, a process linked to inflammation and long-term health problems in cancer survivors and other diseases.

Primary Objective(s):

  • Generate safety data and calculate biodistribution and organ dosimetry in healthy adult volunteers following [18F]fluoroedaravone intravenous administration.
Read the detailed description

Oxidative stress occurs when the body produces more reactive oxygen and nitrogen species than it can remove. Oxidative stress has been linked to inflammation, tissue injury, and a variety of diseases. Researchers believe it may also contribute to long-term health problems experienced by some survivors of childhood cancer, including cognitive difficulties. However, there are currently no clinically available imaging methods that directly measure oxidative stress in living people.

This first-in-human study will evaluate a new investigational PET imaging tracer called[18F]fluoroedaravone ([18F]FEDV). The tracer is designed to detect and measure oxidative stress in the body using positron emission tomography (PET) imaging. Before this tracer can be studied in patient populations, it is important to determine its safety, biodistribution, and radiation dosimetry in healthy adults.

Approximately 10 healthy adult volunteers will be enrolled. Each participant will receive a single intravenous injection of [18F]FEDV followed by a series of PET/CT imaging scans over approximately 3 hours. Researchers will evaluate how the tracer distributes throughout the body, how long it remains in different organs and tissues, and how it is cleared from the body. These data will be used to estimate radiation exposure and identify organs that receive the highest tracer uptake.

Safety will be assessed through monitoring of adverse events, vital signs, electrocardiograms (ECGs), symptom questionnaires, and laboratory testing. Blood and urine samples will be collected before and after tracer administration to assess safety and to better understand the metabolism and elimination of the tracer. Participants will return for a follow-up visit 48 to 96 hours after tracer administration for additional safety evaluations.

The main purpose of this study is to determine whether[18F]FEDV is safe to use in healthy adults and to learn how it moves through and leaves the body after injection. Information from this study will help researchers use this imaging tracer in future studies of oxidative stress in cancer survivors and other health conditions. The long-term goal is to develop a PET imaging tool that can help doctors and researchers better measure oxidative stress in the body.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

St. Jude Children's Research Hospital is the lead sponsor of 440 studies on the registry; 102 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers, 18-75 years of age.
  • signed by participant according to the guidelines of the institutional review board.

Exclusion criteria

Exclusion Criteria:

  • Participants with known underlying genetic disorders or predisposition syndromes that could make them a high risk for being exposed to radiation (such as LiFraumeni).
  • Participant has been treated for cancer.
  • Participant has experienced a stroke.
  • Participant has history of seizures.
  • Participant has been diagnosed with a neurodegenerative or neurodevelopmental disorder.
  • Participant has been diagnosed with a psychiatric disorder such as bipolar or schizophrenia.
  • Participant has been diagnosed or is suspected to have had a traumatic brain injury or concussion (TBI) within the last year.
  • Participant has known disease of the lung, liver, kidneys, gastrointestinal tract, bones/joints, or known immune suppression or disease likely to have active inflammation (examples to exclude: Crohn's disease, , asthma)
  • Participant has prosthetic or indwelling device(s), including IUD, currently, or has had one in the past 60 days.
  • Participant has undergone any major procedure of an internal organ, such as an organ transplant, removal, or corrective surgery.
  • Participant is pregnant, lactating, or breastfeeding due to theoretical potential harm to the infant from exposure to radiation.
  • Estimated \< 45 ml/minute/1.73m2 Participants actively taking anti-inflammatory medication or have a condition requiring them to take anti- inflammatory medication (e.g. NSAIDs or ).
  • Participant has any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol, including being unable to tolerate the PET scan procedures.
  • Inability or unwillingness of research participant or legal guardian/representative to give written .
  • History of to edaravone
  • Male and female participants of who decline or are unable to use effective for the duration of the study and follow-up.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Treatment - [18F]Fluoroedaravone PET Imaging

    Healthy adult volunteers receive a single intravenous injection of \[18F\]fluoroedaravone (\[18F\]FEDV), followed by serial whole-body PET/CT imaging evaluations. Participants also undergo blood collection, urine collection, vital sign monitoring, ECG assessments, symptom questionnaires, and a follow-up safety visit 48 to 96 hours after tracer administration.

    Drug: [18F]Fluoroedaravone ([18F]FEDV) · Procedure: PET/CT Imaging

Interventions

  • Drug[18F]Fluoroedaravone ([18F]FEDV)

    Investigational fluorine-18 labeled edaravone PET radiotracer administered by intravenous injection

  • ProcedurePET/CT Imaging

    Whole-body PET/CT imaging performed following administration of \[18F\]FEDV

06

What researchers measure

Primary outcomes

  1. Evaluate safety of [18F]fluoroedaravone administration in up to 10 human subjects.

    Safety will be assessed by the number and percentage of patients with adverse events following \[18F\]fluoroedaravone administration. Adverse events will be categorized by the FDA's Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.

    Time frame: Baseline at study entry and within 4 days following PET/CT.

  2. Evaluate the biodistribution of [18F]fluoroedaravone in up to 10 human subjects.

    Calculate the absorbed dose of \[18F\]fluoroedaravone in normal organs.

    Time frame: Through study completion, with an average of 3 months post-PET/CT.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of article publication.

Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 3, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Dec 2026
Nov 3, 2026
Eligibility
1 inclusion criterion removed; 2 exclusion criteria edited, 4 added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedFemale participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
Exclusion criteria
  • AddedParticipants with known underlying genetic disorders or predisposition syndromes that could make them a high risk for being exposed to radiation (such as LiFraumeni).
  • EditedParticipant has undergone any major procedure of an internal organ, such as an organ transplant, removal, or corrective surgery.
  • RemovedParticipant is pregnant or breastfeeding.
  • RemovedEstimated glomerular filtration rate < 45 ml/minute/1.73m2
  • AddedParticipant is pregnant, lactating, or breastfeeding due to theoretical potential harm to the infant from exposure to radiation.
  • EditedEstimated glomerular filtration rate < 45 ml/minute/1.73m2 Participants actively taking anti-inflammatory medication or have a condition requiring them to take anti- inflammatory medication (e.g. NSAIDs or steroids).
  • AddedHistory of hypersensitivity to edaravone
  • AddedMale and female participants of childbearing potential who decline or are unable to use effective contraception for the duration of the study and follow-up.
Nov 16, 2026
Show all 3 updates
  1. Nov 16, 2026
    Eligibility 1 inclusion criterion removed; 2 exclusion criteria edited, 4 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedFemale participants of childbearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation.
    Exclusion criteria
    • AddedParticipants with known underlying genetic disorders or predisposition syndromes that could make them a high risk for being exposed to radiation (such as LiFraumeni).
    • EditedParticipant has undergone any major procedure of an internal organ, such as an organ transplant, removal, or corrective surgery.
    • RemovedParticipant is pregnant or breastfeeding.
    • RemovedEstimated glomerular filtration rate < 45 ml/minute/1.73m2
    • AddedParticipant is pregnant, lactating, or breastfeeding due to theoretical potential harm to the infant from exposure to radiation.
    • EditedEstimated glomerular filtration rate < 45 ml/minute/1.73m2 Participants actively taking anti-inflammatory medication or have a condition requiring them to take anti- inflammatory medication (e.g. NSAIDs or steroids).
    • AddedHistory of hypersensitivity to edaravone
    • AddedMale and female participants of childbearing potential who decline or are unable to use effective contraception for the duration of the study and follow-up.
  2. Nov 3, 2026
    Start date Oct 2026→Dec 2026
    + 1 other change: verification date
  3. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07801976
Responsible party
Sponsor
First posted
Sep 3, 2026
Start date
Dec 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Kiel Neumann, PhD
Contact
referralinfo@stjude.org
866-278-5833
Kiel Neumann, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion